(Q53504425)

14 May 2018

title

Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis. (English)

1 reference

14 May 2018

author

Angela Dispenzieri

3

1 reference

14 May 2018

Nelson Leung

7

1 reference

14 May 2018

Martha Q Lacy

2

Martha Lacy

1 reference

14 May 2018

1

Morie Gertz

1 reference

14 May 2018

Suzanne R Hayman

4

Suzanne Hayman

1 reference

14 May 2018

Francis K Buadi

6

Francis Buadi

1 reference

14 May 2018

Mark R Litzow

8

Mark Litzow

1 reference

14 May 2018

Shaji K Kumar

5

Shaji Kumar

1 reference

14 May 2018

publication date

1 January 2008

1 reference

14 May 2018

published in

Leukemia & Lymphoma

1 reference

14 May 2018

volume

49

1 reference

14 May 2018

issue

1

1 reference

14 May 2018

page(s)

36-41

1 reference

14 May 2018

Systemic immunoglobulin light-chain amyloidosis

cites work

1 reference

https://api.crossref.org/works/10.1080%2F10428190701684518

Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701684518

Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701684518

Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701684518

The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701684518

Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701684518

The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701684518

Current and emerging views and treatments of systemic immunoglobulin light-chain (Al) amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701684518

High-dose therapy and autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis: a Center for International Blood and Marrow Transplant Research Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701684518

Multiple myeloma-associated AL amyloidosis: is a distinctive therapeutic approach warranted?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701684518

Autologous transplantation for primary systemic AL amyloidosis is feasible outside a major amyloidosis referral centre: the Calgary BMT Program experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701684518

Autologous stem cell transplantation in primary systemic amyloidosis: the impact of selection criteria on outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701684518

High treatment-related mortality in cardiac amyloid patients undergoing autologous stem cell transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701684518

Early treatment-related mortality in adult autologous stem cell transplant recipients: a nation-wide survey of 1482 transplanted patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701684518

Risk stratification in cardiac amyloidosis: novel approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701684518

Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701684518

Managing systemic light-chain amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701684518

Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701684518

Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701684518

Transplantation for amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701684518

Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701684518

Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701684518

Stem cell transplantation for the management of primary systemic amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701684518

Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701684518

Excessive fluid accumulation during stem cell mobilization: a novel prognostic factor of first-year survival after stem cell transplantation in AL amyloidosis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701684518

Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701684518

Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701684518

Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701684518

Autologous stem cell transplantation for primary systemic amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701684518

Outcome of autologous stem cell transplantation for AL amyloidosis in the UK

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701684518

Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701684518

10.1080/10428190701684518

21 January 2018

Identifiers

DOI

1 reference

14 May 2018

1 reference

14 May 2018